<table border="1" id="i1abcef4b-1acb-4da6-8fa4-60cb40d92995" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1.  Mean and Range of Total Body Clearance and Half-Life of Theophylline Related to Age and Altered Physiological States.¶ </caption>
<tbody>
<tr>
<td>Popular Characteristics<br/>Age<br/>
</td>
<td>Total Body Clearance *<br/>mean (range)††<br/>(mL/kg/min)<br/>
</td>
<td>Half-Life<br/>mean (range)††<br/>(hr)<br/>
</td>
</tr>
<tr>
<td>Premature Neonates<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>postnatal age 3-15 days<br/>
</td>
<td>0.29 (0.09 - 0.49)<br/>
</td>
<td>30 (17 - 43)<br/>
</td>
</tr>
<tr>
<td>postnatal age 25-57 days<br/>
</td>
<td>0.64 (0.04 -1.2)<br/>
</td>
<td>20 (9.4 - 30.6)<br/>
</td>
</tr>
<tr>
<td>Term Infants<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>postnatal age 1 - 2 days<br/>
</td>
<td>NR †<br/>
</td>
<td>25.7 (25 - 26.5)  <br/>
</td>
</tr>
<tr>
<td>postnatal age 3 - 30 days<br/>
</td>
<td>NR †<br/>
</td>
<td>11 (6-19)<br/>
</td>
</tr>
<tr>
<td>Children<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>1 - 4 years</td>
<td>1.7 (0.5 - 2.9)<br/>
</td>
<td>3.4 (1.2 - 5.6)<br/>
</td>
</tr>
<tr>
<td>4 - 12 years<br/>
</td>
<td>1.6 (0.8 - 2.4) <br/>
</td>
<td>NR †</td>
</tr>
<tr>
<td>13 - 15 years<br/>
</td>
<td>0.9 (0.48 - 1.3)<br/>
</td>
<td>NR †</td>
</tr>
<tr>
<td>16-17 years<br/>
</td>
<td>1.4 (0.2 - 2.6)</td>
<td>3.7</td>
</tr>
<tr>
<td>Adults (16 - 60)<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>otherwise healthy<br/>nonsmoking asthmatics<br/>
</td>
<td>0.65 (0.27 - 1.03)<br/>
</td>
<td>8.7 (6.1 - 12.8)<br/>
</td>
</tr>
<tr>
<td>Elderly (more than 60 years)<br/>nonsmokers with normal cardiac,<br/>liver, and renal function<br/>
</td>
<td>0.41 (0.21 - 0.61)<br/>
</td>
<td>9.8 (1.6 - 18)<br/>
</td>
</tr>
<tr>
<td>
<content stylecode="underline">Concurrent Illness or Altered Physiological State</content>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Acute pulmonary edema<br/>
</td>
<td>0.33 ** (0.07 - 2.45)</td>
<td>19 ** (3.1 - 8.2)<br/>
</td>
</tr>
<tr>
<td>COPD- more than 60 years, stable<br/>nonsmoker more than 1 year.<br/>
</td>
<td>0.54 (0.44 - 0.64)<br/>
</td>
<td>11 (9.4 -12.6)<br/>
</td>
</tr>
<tr>
<td>COPD with cor pulmonale<br/>
</td>
<td>0.48 (0.08 - 0.88)<br/>
</td>
<td>NR †</td>
</tr>
<tr>
<td>Cystic Fibrosis (14 - 28 years)<br/>
</td>
<td>1.25 (0.31 - 2.2)<br/>
</td>
<td>6 (1.8 - 10.2)<br/>
</td>
</tr>
<tr>
<td>Fever associated with acute viral respiratory<br/>illness (children 9 - 15 years)<br/>
</td>
<td>NR †</td>
<td>7 (1.0 - 13)<br/>
</td>
</tr>
<tr>
<td>Liver disease-cirrhosis<br/>
</td>
<td>0.31** (0.1 - 0.7)<br/>
</td>
<td>32** (10 - 56)<br/>
</td>
</tr>
<tr>
<td>acute hepatitis<br/>
</td>
<td>0.35 (0.25 - 0.45)<br/>
</td>
<td>19.2 (16.6 - 21.8)<br/>
</td>
</tr>
<tr>
<td>cholestasis<br/>
</td>
<td>0.65 (0.25 - 1.45)<br/>
</td>
<td>14.4 (5.7 - 31.8)<br/>
</td>
</tr>
<tr>
<td>Pregnancey - 1st trimester<br/>
</td>
<td>NR †</td>
<td>8.5 (3.1 - 13.9)<br/>
</td>
</tr>
<tr>
<td>2nd trimester<br/>
</td>
<td>NR †</td>
<td>8.8 (3.8 - 13.8)<br/>
</td>
</tr>
<tr>
<td>3rd trimester<br/>
</td>
<td>NR †</td>
<td>13 (8.4 - 17.6)<br/>
</td>
</tr>
<tr>
<td>Sepsis with multi-organ failure<br/>
</td>
<td>0.47 (0.19-1.9)<br/>
</td>
<td>18.8 (6.3 - 24.1)<br/>
</td>
</tr>
<tr>
<td>Thyroid disease - hypothyroid<br/>
</td>
<td>0.38 (0.13 - 0.57)<br/>
</td>
<td>11.6 (8.2 - 25)<br/>
</td>
</tr>
<tr>
<td>hyperthyroid<br/>
</td>
<td>0.8 (0.68 - 0.97)<br/>
</td>
<td>4.56 (3.7 - 5.6)<br/>
</td>
</tr>
</tbody>
</table>